The European Society for Medical Oncology meeting may not be as enormous as its U.S. counterpart, but plenty of news is flowing. And some of the new data presented in Madrid over the weekend is pretty dramatic.
Diagnostics giant Thermo Fisher Scientific has partnered with GlaxoSmithKline and Pfizer to create a companion diagnostic for solid tumors that will address multiple drug programs. The move is a first step to superseding the often highly fragmented development and use of companion diagnostics to determine the best course of treatment for a particular patient.
The FDA polished up the official label on Pfizer's stop-smoking drug Chantix earlier this week. It was a victory for Pfizer, the payoff from several studies testing the drug for psychiatric side effects. Essentially, the new label will include study data suggesting that patients using the drug might not be at a greater risk of psychiatric problems after all.
Anyone else feel like we need a mind map to keep track of the incestuous M&A talks going on in pharma right now?
Hey, young women: You have plans. Dreams. Goals. And by the way, getting pregnant unexpectedly could throw those visions for your future under the bus. That's the (implicit) message in several newly launched campaigns from Pfizer and Bayer Healthcare, including a pitch for Bayer's new device Skyla supported by a fellow millennial, the actress Zosia Mamet of Girls fame.
Next month, the FDA's expert advisers will take another look at Pfizer's stop-smoking drug Chantix. The official agenda: Weigh new data on Chantix's links to psychiatric side effects, and consider changing the black-box warning about those risks.
Over the last few years we've seen some big changes in the way some drugs are developed. What better time to host a new FierceBiotech executive panel discussion on current trends in late-stage development?
Pfizer and Ranbaxy Laboratories persuaded a U.S. judge to toss out an antitrust lawsuit accusing them of conspiring to delay generic versions of the cholesterol-fighting blockbuster Lipitor.
Remember all those industrial and investment promises Pfizer made when it was trying to snag AstraZeneca earlier this year? The body that polices U.K. dealmaking is eyeing new rules that would give it more power to enforce such promises, should Pfizer--or another company--come calling in the future.
Pfizer needs a tax inversion deal. Without one, it can't properly compete with overseas companies, simple as that. And if AstraZeneca doesn't want to play, Pfizer is willing to look elsewhere. Even if "elsewhere" means a generics company.